Anaemia in patients with advanced cancer receiving palliative care

European Journal of Oncology

Volumn 11, Issue 4, 2006, Pages 225-235

  Tanneberger, Stephan ^a  

^a Fondazione ANT Italia   (Italy)

Author keywords

Anaemia; Cancer; Palliative care

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN;

ADVANCED CANCER; ANEMIA; BLOOD TRANSFUSION; BONE METASTASIS; CANCER PALLIATIVE THERAPY; CANCER PATIENT; FATIGUE; HEMOGLOBIN BLOOD LEVEL; HUMAN; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW;

EID: 33847738198     PISSN: 11286598     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Connes P, Perrey S, Varray A, et al. Faster oxygen uptake kinetics at the onset of submaximal cycling exercise following 4 weeks recombinant human erythropoietin (r-HuEPO) treatment. Pflugers Arch 2003; 447 (2): 231-8.
2. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the asssessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997; 34: 13-9.
3. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alpha on haematologic parameters and quality of life in cancer patients receiving non-platin chemotherapy: results of a randomized double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-74.
4. Lind M, Vernon C, Cruishank D, et al. The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. Br J Cancer 2002; 86: 1243-9.
5. Cella D, Donrez D, Glaspy J. Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol 2003; 14: 511-9.
6. Holzner B, Kemmler G, Greil R, et al. The impact of haemoglobin levels on fatigue and quality of life in cancer patients. Ann Oncol 2002; 13: 965-73.
7. Munch TN, Zhang T, Willey J, et al. The association between anemia and fatigue in patients with advanced cancer receiving palliative care. J Palliat Med 2005; 8 (6): 1144-9.
8. Tanneberger S, Pannuti F, Malavasi I, et al. New challenges and old problems: end-of-life care and the dilemma of prognostic accuracy. Adv Gerontol 2002; 10: 131-5.
9. Tanneberger S, Pannuti F. New challenges for oncology after 2000. Cancer Strategy 2000; 2: 2-6.
10. Tanneberger S, Pannuti F. Krebs im Endstadium. München-Bern-Wien-New York: Zuckschwerdt Verlag, 2001.
11. Tanneberger S, Cavalli F, Pannuti F. Cancer in developing countries. München-Bern-Wien-New York: Zuckschwerdt Verlag, 2004.
12. Rice M. Treating anemia: damned if you do, damned if you do not. Cancer World 2005; 5: 15-20.
13. Wallerstein jr. RO, Deisseroth AB. Bone marrow dysfunction in the cancer patient. In De Vita D jr, Hellmann S, Rosenberg SA (eds). Cancer: principles and practice of oncology, 4th ed. Philadelphia: JB Lippincott, 1993.
14. Birgegard G, Aapro MS, Bokemeyer C, et al. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 2005; 68 suppl. 1; 3-11.
15. Fauci AS, Braunwald E, Isselbacher KI, et al. Harrison's principles of internal medicine - Companion Handbook, 14th ed. New York: Mc Graw-Hill Companies Inc., 1998.
16. Guralnik JM, Ershler WB, Schrier SL, et al. Anemia in the elderly: a public health crisis in hematology. Hematology Am Soc Hematol Educ Program 2005: 528-33.
17. Izaks GJ, Westendorp RG, Knoo DL. The definition of anemia in older persons. JAMA 1999; 281 (18): 1714-7.
18. Nilsson-Ehle H, Jagenburg R, Landahl S, et al. Blood haemoglobin declines in the elderly: implications for reference intervals from age 70 to 88. Eur J Haematol 2000; 65 (5): 297-305.
19. Olde Rikkert MG. The recommended reference values for anaemia in the elderly are of limited usefulness. Ned Tijdschr Geneeskd 2006; 150 (18): 999-1001.
20. Bohlius J, Weingart O, Trelle S, et al. Cancer-related anemia and recombinant human erythropoietin - an updated overview. Nature Clinical Practice Oncology 2006; 3 (3): 152-64.
21. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91: 1616-34.
22. Harper P, Littlewood T. Anemia of cancer: impact on patient fatigue and long-term outcome. Oncology 2005; 69 suppl. 2: 2-7.
23. Azria D, Zouhair A, Serre A, et al. Anemia in head and neck cancers. Bull Cancer 2005; 92 (5): 445-51.
24. Seshadri T, Prince HM, Bell DR, et al. The Australian Cancer Anaemia Survey: a snapshot of anemia in adult patients with cancer. Med J Austr 2005; 182 (9): 453-7.
25. Kosmidis P, Krzakowski M. The ECAS Investigators. Anemia profiles in patients with lung cancer: what have we learned from the European Cancer Anemia Survey (EGAS)? Lung Cancer 2005; 50 (3): 401-12.
26. Dunn A, Carter J, Carter H. Anemia at the end of life: prevalence, significance, and cause in patients receiving palliative care. J Pain Symptom Manage 2003; 26 (6): 1132-9.
27. Tanneberger S, Mellili G, Strocchi E, et al. Use of red blood cell transfusion in palliative care services: is it still up to date or is cancer-related anaemia controlled better with erythropoietic agents? Ann Oncol 2004; 15: 839-40.
28. Catane R, Cherny NI, Kloke M, et al. ESMO handbook of advanced cancer care. London, New York: Tailor and Francis, 2006.
29. Lelli G. Sintomi "segnale" in oncologia clinica. Bologna: Monduzzi Editore, 2005.
30. Palliative Cancer Care. ESO Advanced Course, Stockholm, 7-9 September 2006.
31. Stone P, Hardy J, Broadley K, et al. Fatigue in advanced cancer: a prospective controlled cross-sectional study. Br J Cancer 1999; 79 (9-10): 1479-86.
32. Barnes EA, Bruera E. Fatigue in patients with advanced cancer: a review. Int J Gynecol Cancer 2002; 12 (5): 424-8.
33. Rao A, Cohen HJ. Symptom management in the elderly cancer patient: fatigue, pain, and depression. J Natl Cancer Inst Monograph 2004; 32: 150-7.
34. Pfaff D. Fatigue as a window to the brain. Endocrine 2006; 29 (1): 181-2.
35. Ahmedzai SH. Supportive, palliative and terminal care. In Cavalli F, Hansen H, Kaye SB (eds). Textbook of medical oncology, 2nd ed. London: Dunitz, 2000.
36. Christakis NA, Lamont B. Extent and determinants of error in doctor's prognoses in terminally ill patients: prospective cohort study. Br Med J 2000; 320: 469-72.
37. Vigan A, Dorgan M, Bruera E, et al. The relative accuracy of the clinical estimation of the duration of life for patients with end of life cancer. Cancer 1999; 86: 170-6.
38. Liobera J, Esteva M, Rifa J, et al. Terminal cancer. Duration and prediction of survival time. Eur J Cancer 2000; 36: 2036-43.
39. Tanneberger S, Malavasi I, Mariano P, et al. Planning palliative or terminal care: the dilemma of doctor's prognoses in terminally ill cancer patients. Ann Oncol 2002; 13: 1320-1.
40. Pannuti F, Tanneberger S. Dying with dignity: illusion, hope or human right? World Health Forum 1993; 14: 172-3.
41. Tanneberger S, Pannuti F, Mirri R, et al. Hospital-at-home for advanced cancer patients within the framework of the Bologna Eubiosia project: an evaluation. Tumori 1998; 84: 376-82.
42. Ludwig H. Anemia of hematologic malignancies: what are the treatment options. Semin Oncol 2002; 29 (3 suppl. 8): 45-54.
43. Eagleton HJ, Littlewood TJ. Update of the clinical use and misuse of erythropoietin. Curr Hematol Rep 2003; 2 (2): 109-15.
44. Monti M, Castellani L, Berlusconi A, et al. Use of red blood cell transfusion in terminally ill cancer patients admitted to a palliative care unit. J Pain Symptom Manage 1997; 13: 18-22.
45. Douglas SP, Crook ED, Reynolds MD, et al. "There is power in the blood": a case discussing ethical issues of utility of resources. Am J Med Sec 2001; 322: 145-50.